In a nutshell
This study compared the effectiveness of current treatment options for high-risk prostate cancer (PCa). It found that RP is the preferred treatment option for these patients.
Some background
Prostate surgery (RP) is a common treatment option for high-risk PCa. Radiation therapy (RT), androgen deprivation therapy (ADT) and brachytherapy (BT) are other options. RT can be given as external beam radiation therapy (EBRT) or BT. EBRT is when the radiation source is outside the body. BT a form of RT where a radiation source is placed next to the area requiring treatment (inside the body). ADT is an antihormone therapy to reduce levels of testosterone in the body. These options can be combined.
It is unclear which option is the best for patients with high-risk PCa.
Methods & findings
This study reviewed the 10-year outcomes of 6296 patients treated for PCa. Group A had RP. Group B had EBRT and ADT. Group C had EBRT and BT and ADT. Group D had EBRT and BT without ADT.
Groups C and D had a higher overall survival (by 53%) compared to Group A. However, groups C and D had higher costs compared to group A. Group B had a 2.19 times higher mortality rate related to PCa and complications related to PCa compared to Group A. Groups C and D had the highest bowel and bladder side-effects, compared to group A. These include pain, constipation or urine urgency.
The bottom line
This study found that RP is the preferred treatment option for high-risk prostate cancer patients.
The fine print
This study was based on patients treated between 1996 and 2003. Treatment options and medical care has significantly changed. Newer studies are needed.
Published By :
Urologic oncology
Date :
Jul 05, 2019
